Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD2284
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AZD2284 is an investigational radioligand therapy currently in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is being developed as a targeted therapy, where the molecule is conjugated with Actinium-225, a radioactive isotope. The drug is designed to deliver targeted radiation to cancer cells expressing specific biomarkers such as Prostate-Specific Membrane Antigen (PSMA) and Six-Transmembrane Epithelial Antigen of Prostate 2 (STEAP2), which are prevalent in advanced prostate cancers. The mechanism involves using an antibody or ligand that binds these antigens on tumor cells, allowing precise delivery of alpha-emitting radiation from Actinium-225 to induce cytotoxicity and cell death in malignant tissue while sparing normal cells. This approach aims to improve efficacy and reduce off-target toxicity compared to conventional therapies[5][7].
- Other names
- 225Ac-AZD2284
02
Targets
PSMA (Prostate-specific membrane antigen)STEAP2 (Six-transmembrane epithelial antigen of the prostate 2)
Beyond the preview
Go deeper on AZD2284.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD2284.